This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Immunomedics Highlights Clinical Pipeline For Solid Cancer And Lupus Therapy At R & D Day

MORRIS PLAINS, N.J., April 23, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced a historical milestone in the Company's listing at the NASDAQ stock market, which is going on 30 years strong. Only a small, elite group of biopharmaceutical companies has this longevity.

After ringing the opening bell at NASDAQ, the Company held its Research and Development Day for analysts and institutional investors, highlighting the 3 major pillars that are the value drivers for the Company: epratuzumab, (anti-CD22 humanized antibody), from which top-line data from the two Phase III registration trials in patients with moderate to severe lupus is expected first quarter 2015 by partner UCB; yttrium-90 ( 90Y)-labeled clivatuzumab tetraxetan that is being evaluated in a Phase III trial to treat patients with advanced pancreatic cancer; and the two antibody-drug conjugates (ADCs) for solid tumor therapy, IMMU-132 and IMMU-130, which are progressing in Phase II trials.

"In addition," Company President and Chief Executive Officer, Cynthia L. Sullivan, emphasized, "we are advancing other product candidates in earlier-stage clinical trials as well as other novel technologies in preclinical studies."

Dr. David M. Goldenberg, Chairman and Chief Scientific Officer, introduced the science underlying the agents in clinical trials, beginning with new information on the mechanism of action of epratuzumab, followed by the Company's proprietary linker for conjugating SN-38 to the two ADCs. Before introducing the clinical investigators who summarized their experiences with the Company's most advanced therapeutics, Dr. Goldenberg also described the scientific efforts to develop a novel and potent T-cell immunotherapy for solid cancers.

Dr. Michael J. Guarino, medical oncologist at the Christiana Care Health System, Helen F. Graham Cancer Center, in Newark, DE, summarized the current status of the clinical trials with IMMU-130, the Company's ADC targeting CEACAM5 for colorectal cancers therapy, including two cases where IMMU-130 was able to shrink the patients' colonic cancer metastases 52% and 66%, respectively. "The second patient is being treated at our center for almost 9 months, receiving doses twice weekly during this time, without evidence of major side effects or any immune reaction to the ADC; the patients had 4 prior therapies before entering this trial," Dr. Guarino explained.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs